EBI Expands Its Leadership in Bone Growth Stimulation Through Acquisition of Xstim

EBI Expands Leadership in Bone Growth Stimulation

In a significant move to strengthen its market presence, EBI, a pioneer in electrobiology innovations, announced its acquisition of Xstim, a division under Precision Medical Products Inc. This strategic acquisition not only reinforces EBI's status as a leader in the bone growth stimulation sector but also introduces cutting-edge technology to its existing product lineup.

About EBI and its Recent Acquisition

Founded over 45 years ago, EBI has consistently been at the forefront of electrobiology, specializing in innovative solutions for bone healing. As the only pure-play company in bone growth stimulation, EBI has continuously evolved, focusing on clinically proven implantable and non-invasive solutions. The recent addition of Xstim enhances EBI's offerings significantly.

Xstim specializes in developing next-generation solutions aimed at improving spinal fusion outcomes. Their flagship product utilizes capacitively coupled electrical stimulation, providing a modern therapy option designed to enhance patient comfort and usability. This unique technology is designed to tackle challenges in areas such as lumbar spinal fusion, nonunion fractures, and failed joint fusions, making it a highly complementary addition to EBI's robust portfolio.

Advantages for Surgeons and Patients

The integration of Xstim's capabilities into EBI's existing platform empowers surgeons and healthcare teams with a broader array of options. Surgeons can now offer patients a mix of traditional and cutting-edge treatments tailored to their unique needs. With the synthesized strengths of both companies, patients can expect improved outcomes and more effective healing strategies across various conditions that require bone growth stimulation.

Kevin Kenny, EBI's CEO, underscored the strategic importance of this acquisition: "Our vision is clear to be the trusted market leader in bone growth stimulation, and the addition of Xstim further supports our mission of improving patient outcomes through innovative solutions. This acquisition allows us to enhance our research and development pipeline to meet the evolving needs of healthcare providers and patients alike."

Supporting EBI's Vision

The collaboration comes at a time when the demand for effective bone healing solutions is on the rise. Nonhealing fractures and joint fusion complications pose significant challenges in patient recovery and care. EBI’s comprehensive portfolio, including products like the EBI® Bone Healing System and OsteoGen™, already plays a pivotal role in addressing these concerns. With the addition of Xstim, EBI aims to advance the next generation of bone healing technologies significantly.

The acquisition was facilitated with the assistance of Ropes & Gray LLP, serving as legal counsel to EBI, while William Blair acted as the exclusive financial advisor. Precision Medical Products also had Perkins Coie assist in legal matters during the transaction.

Future Endeavors

As EBI prepares for the integration of Xstim into its offerings, the company emphasizes its commitment to Helping People Heal™. The focus remains on delivering top-notch solutions that make a difference in patients’ lives. With a strong foundation built on decades of experience and innovation, EBI is set to lead advancements in bone growth stimulation technology, making treatments more accessible and effective for healthcare providers and their patients.

With this acquisition, EBI not only enhances its product range but also strengthens its competitive position in the healthcare industry, paving the way for future innovations that will undoubtedly benefit countless individuals in need of effective and reliable bone healing solutions.

For further details, visit www.ebibonestimulator.com.

Conclusion

The merger of EBI and Xstim marks a new chapter in the evolution of bone growth technologies, promising improved clinical outcomes and setting new standards in patient care. As the company navigates this transition, patients and healthcare providers can look forward to enhanced treatment modalities designed to heal more effectively than ever before.